Creative Touch Permanent Makeup and Aesthetics

IL-6 is worth understanding precisely because it sits at the intersection of two things that look similar on the surface but are mechanistically opposite: the therapeutic inflammation that drives treatment outcomes, and the chronic inflammatory environment that drives skin ageing. Getting that distinction clear, for the clinic’s own treatment rationale and for client conversations, is where this entity earns its place.

Acute Inflammation Is Not the Enemy

One of the more useful reframes for clients who are anxious about post-procedure redness, swelling, or heat is that acute IL-6 activity is part of what makes the treatment work. In the immediate post-procedure window following RF microneedling, microneedling, or IPL, the controlled injury triggers an IL-6 release from mast cells, macrophages, and fibroblasts at the treatment site. This acute IL-6 signal – operating through classical signalling and regenerative JAK/STAT3 – promotes keratinocyte migration, fibroblast recruitment, and the transition into the proliferative healing phase. Suppressing this response aggressively with anti-inflammatories in the immediate post-procedure window may attenuate the remodelling response the treatment is intended to produce.

The practical guidance: post-procedure redness and mild swelling are not complications to eliminate, they are the visible surface of a healing process that includes the collagen synthesis response the client has come in for. What we are managing is duration and intensity, not abolition. That reframe tends to land well with clients who equate visible inflammation with something going wrong.

Chronic IL-6 and the Ageing Skin Environment

The same cytokine that supports acute healing becomes, in the context of senescent fibroblast SASP, one of the primary mechanisms through which aged skin degrades. Senescent fibroblasts secrete IL-6 continuously through trans-signalling – a pro-inflammatory mode – reinforcing their own senescent state and inducing paracrine senescence in neighbouring non-senescent fibroblasts. The result is a low-grade chronic inflammatory environment – inflammageing – characterised by persistent MMP upregulation, collagen degradation, and progressively impaired fibroblast synthetic function.

This is the environment most clients with significantly photoaged or hormonally depleted skin are presenting with, whether or not they would describe it in those terms. The skin that recovers slowly, bruises easily, loses volume faster than expected, and responds less robustly to treatments than it once did is often operating against a backdrop of elevated chronic IL-6 activity in the dermis.

What Treatments Are Actually Doing to IL-6

Understanding IL-6’s dual role clarifies why our treatment sequencing prioritises senescent cell burden reduction before volume restoration, and why polynucleotides sit logically at the beginning of a treatment plan for significantly aged presentations.

Polynucleotides suppress NF-κB signalling in fibroblasts, reducing the transcriptional output of the SASP programme, which includes IL-6, IL-1β, MMP-1, and MMP-3. This is an environment-focused mechanism: reducing the chronic inflammatory burden rather than directly adding structural components. For a dermis operating under sustained IL-6 trans-signalling, polynucleotides lower the background noise that is actively degrading the matrix into which any subsequent intervention will be placed.

RF microneedling addresses the senescent fibroblast population itself – the source of chronic IL-6 rather than the signal downstream. RF-induced thermal stress triggers p21 suppression and IGF-1 restoration in surviving fibroblasts, effectively reducing the proportion of senescent cells in the treated tissue. Fewer senescent cells means reduced SASP output, reduced chronic IL-6 levels, and a dermis that is genuinely more receptive to growth factor and mechanical stimulation from subsequent treatments. The IL-6 that follows the RF session is acute, regenerative, and time-limited – mechanistically distinct from the chronic trans-signalling it is helping to displace.

iPRF delivers growth factors – PDGF, TGF-β1, IGF-1 – into a tissue environment that treatments have worked to reduce the chronic inflammatory burden in. TGF-β1 in particular has established activity suppressing SASP expression including IL-6 in fibroblasts, adding a second layer of chronic inflammation modulation alongside its direct collagen synthesis stimulation.

For Client Conversations

Most clients asking about treatment rationale are not asking for a cytokine biology lecture, but the underlying logic translates cleanly into plain language. The version that works in practice:

“As skin ages, some of the cells in the dermis shift from producing collagen to producing low-level inflammation instead. That inflammation actively breaks down the structure around them. What we’re doing with this treatment plan is first reducing that inflammatory background, so the skin stops working against itself, and then stimulating the cells that are still functional to produce more of what the skin needs. The redness after treatment is a different kind of inflammation: it’s the repair signal, not the background damage signal. They look the same from the outside but they’re doing opposite things.”

That framing – repair signal vs background damage signal – is the IL-6 duality in client-facing language. It’s accurate, it’s useful, and it makes the treatment sequencing logic feel coherent rather than arbitrary.